Approval brings patients first new rFIX treatment option in more than 15 years DEERFIELD, Ill.--June 27, 2013--Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug ...
Hemophilia B causes a deficiency in factor IX, a protein necessary for blood clotting. Replacement factor IX therapy is the gold standard treatment, but novel and genetic therapies are showing promise ...
Biogen Idec and Swedish Orphan Biovitrum (Sobi) announced positive results from B-LONG, a global, open-label, multi-center Phase 3 clinical study that evaluated the efficacy, safety and ...
KING OF PRUSSIA, Pa., March 4, 2016 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved IDELVION® [Coagulation Factor IX (Recombinant), Albumin ...
ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety ...
The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product. Switching patients with ...
A long-acting coagulation factor treatment of patients with hemophilia B is safe and effective for preventing bleeding events, according to an article published online December 4 and in the December ...
STOCKHOLM, Sweden--(BUSINESS WIRE)--Jan. 23, 2006--Biovitrum AB, Sweden, and Syntonix Pharmaceuticals, Inc., USA, have entered into a co-development and commercialization agreement for Syntonix' ...
HATTERSHEIM, Germany, July 3, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) has approved the new Summary of Product ...
The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first ...
Potential Biomarker, Drug Target ID’d for Adult Leukemia Prophylactic rFIXFc, administered every one to two weeks, resulted in low annualized bleeding rates in patients with hemophilia B. (HealthDay ...
Following are specific recommended plasma levels and actions for common bleeding problems and clinical situations which occur with Hemophilia B, also known as Factor IX Deficiency: Assess situation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback